Heart and Vessels

, Volume 34, Issue 10, pp 1608–1614 | Cite as

Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study

  • Fumeng Yang
  • Liping Ma
  • Lili Zhang
  • Yilian Wang
  • Changxin Zhao
  • Wenjun Zhu
  • Wei Liang
  • Qian LiuEmail author
Original Article


Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a newly emerging biomarker with strong pro-inflammatory effects, and is an independent risk predictor of atherosclerotic plaque rupture and thrombosis. In addition, ischemic modified albumin (IMA) is another important marker for the evaluation of myocardial ischemia, and has been approved by the U.S. Food and Drug Administration. The objective of this study was to investigate serum Lp-PLA2 and IMA in the early diagnosis, progression and prognosis of acute coronary syndrome (ACS). Serum Lp-PLA2 and IMA were detected using an AU5800 automatic biochemical analyzer in samples from 180 patients with ACS [n = 60 with unstable angina pectoris (UA), n = 56 with non-ST segment elevation myocardial infarction (NSTEMI), and n = 64 with ST segment elevation myocardial infarction (STEMI)] and 60 healthy control subjects. The relationship between Lp-PLA2 and IMA with Gensini score and the number of coronary artery lesions was explored, and logistic regression was conducted to identify risk factors for major adverse cardiovascular events (MACE). Serum Lp-PLA2 and IMA were significantly higher in all ACS subgroups compared to the control group (P < 0.05), were positively associated with the severity of ACS based on the Gensini score (P < 0.05), and were significantly higher in patients with double- and triple-vessel lesions compared to those with single-vessel lesions and healthy controls (P < 0.05). Logistic regression identified Lp-PLA2, IMA, and troponin I levels as independent risk factors for MACE. Lp-PLA2 and IMA were predictive of the degree of myocardial ischemia in patients with ACS, and may provide important clinical significance for the early diagnosis of ACS and the choice of treatment strategy.


Acute coronary syndrome Lipoprotein-associated phospholipase A2 Ischemia-modified albumin Gensini score Major adverse cardiovascular events 



Acute coronary syndrome


Confidence interval


High-density lipoprotein cholesterol


Ischemic modified albumin


Low-density lipoprotein cholesterol


Lipoprotein-associated phospholipase A2


Major adverse cardiovascular events


Non-ST segment elevation myocardial infarction


Odds ratio


Percutaneous coronary intervention


ST segment elevation myocardial infarction


Total cholesterol




Troponin I


Unstable angina pectoris


Author contributions

FY and QL conceived and designed the experiments. LZ, YW, and CZ performed the experiments. WZ, WL and LM analyzed the data. FY, LM, and QL wrote or revised the manuscript. All the authors approved the final submitted version of the manuscript.


Research projects of Bengbu Medical College (BYKY17184, 18178), Young and Middle-aged Talents Growth Foundation of the Second People’s Hospital of Lianyungang (TQ201709), and Health Scientific Research Project in Lianyungang (201721, 201817).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest with this work.


  1. 1.
    Emergency Medical Branch of Chinese Mdical Doctor Association, Cardiovascular Epidemiology Branch of Chinese Medical Association, Laboratory Medicine Branch of Chinese Medical Association (2016) Emergency rapid diagnosis and treatment of guidelines acute coronary syndrome. Chin J Emerg Med 25:397–404Google Scholar
  2. 2.
    Garadah TS, Thani KB, Sulibech L, Jaradat AA, Al Alawi ME, Amin H (2018) Risk Stratification and in Hospital Morality in Patients Presenting with Acute Coronary Syndrome (ACS) in Bahrain. Open Cardiovasc Med J 12:7–17CrossRefGoogle Scholar
  3. 3.
    Gurumurthy P, Borra SK, Yeruva RKR, Victor D, Babu S, Cherian KM (2014) Estimation of ischemia modified albumin (IMA) levels in patients with acute coronary syndrome. Indian J Clin Biochem 29:367–371CrossRefGoogle Scholar
  4. 4.
    Huang Y, Wu Y, Yang Y, Li W, Lu J, Hu Y (2017) Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China. Sci Rep 7:16092CrossRefGoogle Scholar
  5. 5.
    Liu H, Yao Y, Wang Y, Ji L, Zhu K, Hu H, Chen J, Yang J, Cui Q, Geng B, Liu Q, Li D, Zhou Y (2018) Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: a cross-sectional study. J Cell Mol Med 22:5145–5150CrossRefGoogle Scholar
  6. 6.
    Ge PC, Chen ZH, Pan RY, Ding XQ, Liu JY, Jia QW, Liu Z, He SZ, An FH, Li LH, Li ZY, Gu Y, Zhu TB, Li CJ, Wang LS, Ma WZ, Yang ZJ, Jia EZ (2016) Synergistic effect of lipoprotein-associated phospholipase A2 with classical risk factors on coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem 40:953–968CrossRefGoogle Scholar
  7. 7.
    Benderly M, Sapir B, Kalter-Leibovici O, Zimlichman R (2017) Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers 22:219–224CrossRefGoogle Scholar
  8. 8.
    Bhakthavatsala Reddy C, Cyriac C, Desle HB (2014) Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes. Indian Heart J 66:656–662CrossRefGoogle Scholar
  9. 9.
    Sygitowicz G, Janas J, Białek S, Pręgowski J, Pera L, Sitkiewicz D (2013) Ischaemia modified albumin in patients with acute coronary syndrome and negative cardiac troponin I. Scand J Clin Lab Invest 73:130–134CrossRefGoogle Scholar
  10. 10.
    Li D, Wei W, Ran X, Yu J, Li H, Zhao LZ, Zeng HL, Cao Y, Zeng Z, Wang Z (2017) Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: a systematic review and meta-analysis. Clin Chim Acta 471:38–45CrossRefGoogle Scholar
  11. 11.
    Yang L, Liu Y, Wang S, Liu T, Cong H (2017) Association between Lp-PLA2 and coronary heart disease in Chinese patients. J Int Med Res 45:159–169CrossRefGoogle Scholar
  12. 12.
    Mishra B, Pandey S, Niraula SR, Rai BK, Karki P, Baral N, Lamsal M (2018) Utility of ischemia modified albumin as an early marker for diagnosis of acute coronary syndrome. J Nepal Health Res Counc 16:16–21CrossRefGoogle Scholar
  13. 13.
    Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK (2014) 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 64:1929–1949CrossRefGoogle Scholar
  14. 14.
    O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:485–510CrossRefGoogle Scholar
  15. 15.
    Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, ACC/AHA Task Force Members; Society for Cardiovascular Angiography, and Interventions, and the Society of Thoracic Surgeons (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130:2354–2394CrossRefGoogle Scholar
  16. 16.
    Zhang C, Liu P, Xia K, Fang H, Jiang M, Xie Q, Yu Z, Yang T (2017) Association of serum prealbumin with angiographic severity in patients with acute coronary syndrome. Med Sci Monit 23:4041–4049CrossRefGoogle Scholar
  17. 17.
    Chen PM, Ohno M, Hiwasa T, Nishi K, Saijo S, Sakamoto J, Morita Y, Matsuda S, Watanabe S, Kuwabara Y, Ono K, Imai M, Inoue K, Murai T, Inada T, Tanaka M, Kita T, Kimura T, Nishi E (2017) Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Int J Cardiol 243:1–8CrossRefGoogle Scholar
  18. 18.
    Younus A, Humayun C, Ahmad R, Ogunmoroti O, Kandimalla Y, Aziz M, Malik R, Saand AR, Valdes C, Badlani R, Younus MA, Ali SS, Chen Y, Nasir K (2017) Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. J Clin Lipidol 11:328–337CrossRefGoogle Scholar
  19. 19.
    De Mauri A, Vidali M, Chiarinotti D, Bellomo G, Rolla R (2018) Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients. J Nephrol doi: 10.1007/s40620-018-0521-3Google Scholar
  20. 20.
    Kocak S, Ertekin B, Girisgin AS, Dundar ZD, Ergin M, Mehmetoglu I, Bodur S, Cander B (2017) Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke. Turk J Emerg Med 17:56–60CrossRefGoogle Scholar
  21. 21.
    Lu J, Niu D, Zheng D, Zhang Q, Li W (2018) Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk. Biomed Rep 9:517–522Google Scholar
  22. 22.
    Li J, Wang H, Tian J, Chen B, Du F (2018) Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome. Medicine (Baltimore) 97:e11517CrossRefGoogle Scholar
  23. 23.
    Oran I, Oran B (2017) Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of "N-Terminal Modification" to "Fatty Acid Occupation" of Albumin. Dis Markers 2017:5692583CrossRefGoogle Scholar
  24. 24.
    Demir MT, Baydin A, Amanvermez R, Erenler AK, Güzel M, Yücel O (2018) Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome. Bratisl Lek Listy 119:509–512Google Scholar
  25. 25.
    Turan T, Akyüz AR, Sahin S, Kul S, Yilmaz AS, Kara F, Mentese SO, Aykan AÇ, Demir S, Celik S, Karahan SC (2017) Association between the plasma levels of IMA and coronary atherosclerotic plaque burden and ischemic burden in early phase of non-ST-segment-elevation acute coronary syndromes. Eur Rev Med Pharmacol Sci 21:576–583Google Scholar
  26. 26.
    Wahab MAKA (2017) Ischemia modified albumin (IMA) in acute coronary syndrome (ACS) and left bundle branch block (LBBB). Does it make the difference? Egypt Heart J 69:183–190CrossRefGoogle Scholar
  27. 27.
    Ertekin B, Kocak S, Defne Dundar Z, Girisgin S, Cander B, Gul M, Doseyici S, Mehmetoglu I, Kemal Sahin T (2013) Diagnostic value of ischemia-modified albumin in acute coronary syndrome and acute ischemic stroke. Pak J Med Sci 29:1003–1007CrossRefGoogle Scholar
  28. 28.
    Mehta MD, Marwah SA, Ghosh S, Shah HN, Trivedi AP, Haridas N (2015) A synergistic role of ischemia modified albumin and high-sensitivity troponin T in the early diagnosis of acute coronary syndrome. J Family Med Prim Care 4:570–575CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Laboratory MedicineThe Second People’s Hospital of LianyungangLianyungangPeople’s Republic of China
  2. 2.Department of EmergencyThe Second People’s Hospital of LianyungangLianyungangPeople’s Republic of China
  3. 3.Department of CardiovascularThe Second People’s Hospital of LianyungangLianyungangPeople’s Republic of China

Personalised recommendations